1	6	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	What	_	_	WP	_	_	_	_	_
2	do	_	_	VBP	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	Clinical	_	_	JJ	_	_	_	_	_
5	Data	_	_	NN	_	_	_	_	_
6	Teach	_	_	NN	_	_	_	_	_
7	Us	_	_	PRP	_	_	_	_	_
8	?	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	discussed	_	_	VBN	_	_	_	_	_
3	above	_	_	RB	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	great	_	_	JJ	_	_	_	_	_
7	majority	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	radiobiological	_	_	JJ	_	_	_	_	_
11	investigations	_	_	NNS	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	done	_	_	VBN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	very	_	_	RB	_	_	_	_	_
17	radioresistant	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	hyper-radiosensitive	_	_	JJ	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	hyper-radiosensitive	_	_	JJ	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	hyper-radioresistant	_	_	JJ	_	_	_	_	_
7	cellular	_	_	JJ	_	_	_	_	_
8	models	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	representative	_	_	JJ	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	clinical	_	_	JJ	_	_	_	_	_
15	reality	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	example	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	there	_	_	EX	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	no	_	_	DT	_	_	_	_	_
7	known	_	_	VBN	_	_	_	_	_
8	human	_	_	JJ	_	_	_	_	_
9	genetic	_	_	JJ	_	_	_	_	_
10	syndromes	_	_	NNS	_	_	_	_	_
11	caused	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	mutations	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	Ku	_	_	NNP	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	DNA-PKcs	_	_	NNP	_	_	_	_	_
18	proteins	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	major	_	_	JJ	_	_	_	_	_
22	NHEJ	_	_	NN	_	_	_	_	_
23	actors	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	only	_	_	JJ	_	_	_	_	_
3	human	_	_	JJ	_	_	_	_	_
4	case	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	gross	_	_	JJ	_	_	_	_	_
7	defect	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	NHEJ	_	_	NNP	_	_	_	_	_
10	function	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	non-viability	_	_	NN	_	_	_	_	_
13	was	_	_	VBD	_	_	_	_	_
14	caused	_	_	VBN	_	_	_	_	_
15	by	_	_	IN	_	_	_	_	_
16	mutations	_	_	NNS	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	DNA	_	_	NNP	_	_	_	_	_
19	ligase	_	_	NN	_	_	_	_	_
20	IV	_	_	NNP	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	LIG4	_	_	NNP	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	majority	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	cases	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	fatal	_	_	JJ	_	_	_	_	_
7	post-radiotherapy	_	_	NN	_	_	_	_	_
8	events	_	_	NNS	_	_	_	_	_
9	were	_	_	VBD	_	_	_	_	_
10	encountered	_	_	VBN	_	_	_	_	_
11	after	_	_	IN	_	_	_	_	_
12	whole-body	_	_	JJ	_	_	_	_	_
13	irradiation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	children	_	_	NNS	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	ataxia	_	_	NN	_	_	_	_	_
18	telangiectasia	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	AT	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	caused	_	_	VBN	_	_	_	_	_
23	by	_	_	IN	_	_	_	_	_
24	homozygous	_	_	JJ	_	_	_	_	_
25	ATM	_	_	NN	_	_	_	_	_
26	mutations	_	_	NNS	_	_	_	_	_
27	during	_	_	IN	_	_	_	_	_
28	their	_	_	PRP$	_	_	_	_	_
29	anti-leukemia	_	_	NN	_	_	_	_	_
30	or	_	_	CC	_	_	_	_	_
31	lymphoma	_	_	NN	_	_	_	_	_
32	treatment	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	important	_	_	JJ	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	note	_	_	VB	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	AT	_	_	NNP	_	_	_	_	_
8	frequency	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	about	_	_	RB	_	_	_	_	_
12	1/100,000	_	_	CD	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	By	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	about	_	_	RB	_	_	_	_	_
5	5	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	–	_	_	:	_	_	_	_	_
8	20	_	_	CD	_	_	_	_	_
9	%	_	_	NN	_	_	_	_	_
10	cancer	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	treated	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	radiotherapy	_	_	NN	_	_	_	_	_
16	exhibit	_	_	VBP	_	_	_	_	_
17	post-radiotherapy	_	_	NN	_	_	_	_	_
18	tissue	_	_	NN	_	_	_	_	_
19	reactions	_	_	NNS	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	can	_	_	MD	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	considered	_	_	VBN	_	_	_	_	_
24	as	_	_	IN	_	_	_	_	_
25	moderate	_	_	JJ	_	_	_	_	_
26	radiosensitivity	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Surprisingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	no	_	_	DT	_	_	_	_	_
4	or	_	_	CC	_	_	_	_	_
5	very	_	_	RB	_	_	_	_	_
6	few	_	_	JJ	_	_	_	_	_
7	rodent	_	_	NN	_	_	_	_	_
8	cells	_	_	NNS	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	moderate	_	_	JJ	_	_	_	_	_
11	radiosensitivity	_	_	NN	_	_	_	_	_
12	have	_	_	VBP	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	subject	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	published	_	_	VBN	_	_	_	_	_
19	radiobiological	_	_	JJ	_	_	_	_	_
20	characterization	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	some	_	_	DT	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	proteins	_	_	NNS	_	_	_	_	_
7	whose	_	_	WP$	_	_	_	_	_
8	mutations	_	_	NNS	_	_	_	_	_
9	are	_	_	VBP	_	_	_	_	_
10	responsible	_	_	JJ	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	these	_	_	DT	_	_	_	_	_
13	syndromes	_	_	NNS	_	_	_	_	_
14	were	_	_	VBD	_	_	_	_	_
15	cited	_	_	VBN	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	components	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	different	_	_	JJ	_	_	_	_	_
21	variants	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	A-NHEJ	_	_	NNP	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	see	_	_	VB	_	_	_	_	_
26	Section	_	_	NN	_	_	_	_	_
27	4	_	_	CD	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	genetic	_	_	JJ	_	_	_	_	_
6	syndromes	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	associated	_	_	VBN	_	_	_	_	_
9	or	_	_	CC	_	_	_	_	_
10	not	_	_	RB	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	cancer	_	_	NN	_	_	_	_	_
13	proneness	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	different	_	_	JJ	_	_	_	_	_
16	from	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	precited	_	_	JJ	_	_	_	_	_
19	ones	_	_	NNS	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	also	_	_	RB	_	_	_	_	_
22	show	_	_	VB	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	moderate	_	_	JJ	_	_	_	_	_
25	radiosensitivity	_	_	NN	_	_	_	_	_
26	:	_	_	:	_	_	_	_	_
27	this	_	_	DT	_	_	_	_	_
28	is	_	_	VBZ	_	_	_	_	_
29	notably	_	_	RB	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	case	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	neurofibromatosis	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	Huntington	_	_	NNP	_	_	_	_	_
36	’s	_	_	POS	_	_	_	_	_
37	chorea	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	tuberous	_	_	JJ	_	_	_	_	_
41	sclerosis	_	_	NN	_	_	_	_	_
42	syndromes	_	_	NNS	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	must	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	stressed	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	these	_	_	DT	_	_	_	_	_
7	syndromes	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	caused	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	mutations	_	_	NNS	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	cytoplasmic	_	_	JJ	_	_	_	_	_
14	proteins	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	may	_	_	MD	_	_	_	_	_
18	contradict	_	_	VB	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	historical	_	_	JJ	_	_	_	_	_
21	hypothesis	_	_	NN	_	_	_	_	_
22	that	_	_	IN	_	_	_	_	_
23	nucleus	_	_	NN	_	_	_	_	_
24	is	_	_	VBZ	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	most	_	_	RBS	_	_	_	_	_
27	radiosensitive	_	_	JJ	_	_	_	_	_
28	part	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	cell	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	see	_	_	VB	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	Introduction	_	_	NN	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	contradicts	_	_	VBZ	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	hypothesis	_	_	NN	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	defect	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	DSB	_	_	NN	_	_	_	_	_
12	repair	_	_	NN	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	unique	_	_	JJ	_	_	_	_	_
16	cause	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	cellular	_	_	JJ	_	_	_	_	_
19	radiosensitivity	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	question	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	how	_	_	WRB	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	build	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	unified	_	_	JJ	_	_	_	_	_
9	model	_	_	NN	_	_	_	_	_
10	that	_	_	WDT	_	_	_	_	_
11	would	_	_	MD	_	_	_	_	_
12	describe	_	_	VB	_	_	_	_	_
13	both	_	_	DT	_	_	_	_	_
14	hyper-radiosensitivity	_	_	NN	_	_	_	_	_
15	observed	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	LIG4	_	_	NN	_	_	_	_	_
18	-	_	_	:	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	ATM	_	_	NN	_	_	_	_	_
21	-mutated	_	_	VBN	_	_	_	_	_
22	cells	_	_	NNS	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	moderate	_	_	JJ	_	_	_	_	_
25	radiosensitivity	_	_	NN	_	_	_	_	_
26	caused	_	_	VBN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	impairment	_	_	NN	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	alternative	_	_	JJ	_	_	_	_	_
31	signaling	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	DSB	_	_	NN	_	_	_	_	_
34	repair	_	_	NN	_	_	_	_	_
35	pathways	_	_	NNS	_	_	_	_	_
36	remains	_	_	VBZ	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	date	_	_	VB	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	ATM	_	_	NNP	_	_	_	_	_
6	protein	_	_	NN	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	considered	_	_	VBN	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	early	_	_	JJ	_	_	_	_	_
13	actor	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	DSB	_	_	NNP	_	_	_	_	_
17	recognition	_	_	NN	_	_	_	_	_
18	via	_	_	IN	_	_	_	_	_
19	its	_	_	PRP$	_	_	_	_	_
20	phosphorylation	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	H2AX	_	_	NNP	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	individual	_	_	JJ	_	_	_	_	_
26	radiation	_	_	NN	_	_	_	_	_
27	response	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	Surprisingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	ATM	_	_	NNP	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	integrated	_	_	VBN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	all	_	_	PDT	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	DSB	_	_	NNP	_	_	_	_	_
12	repair	_	_	NN	_	_	_	_	_
13	models	_	_	NNS	_	_	_	_	_
14	discussed	_	_	VBN	_	_	_	_	_
15	above	_	_	RB	_	_	_	_	_
16	while	_	_	IN	_	_	_	_	_
17	mutations	_	_	NNS	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	RAD51	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	RAD52	_	_	NNP	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	HR	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	Ku	_	_	NNP	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	DNA-PKcs	_	_	NNP	_	_	_	_	_
30	(	_	_	-LRB-	_	_	_	_	_
31	for	_	_	IN	_	_	_	_	_
32	NHEJ	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	do	_	_	VBP	_	_	_	_	_
35	not	_	_	RB	_	_	_	_	_
36	cause	_	_	VB	_	_	_	_	_
37	any	_	_	DT	_	_	_	_	_
38	viable	_	_	JJ	_	_	_	_	_
39	syndromes	_	_	NNS	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	humans	_	_	NNS	_	_	_	_	_
42	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	delay	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	radiation-induced	_	_	JJ	_	_	_	_	_
8	nucleo-shuttling	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	ATM	_	_	NN	_	_	_	_	_
11	protein	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	RIANS	_	_	NNP	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	was	_	_	VBD	_	_	_	_	_
16	shown	_	_	VBN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	reliable	_	_	JJ	_	_	_	_	_
21	parameter	_	_	NN	_	_	_	_	_
22	for	_	_	IN	_	_	_	_	_
23	predicting	_	_	VBG	_	_	_	_	_
24	radiosensitivity	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	to	_	_	TO	_	_	_	_	_
27	provide	_	_	VB	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	biologically	_	_	RB	_	_	_	_	_
30	relevant	_	_	JJ	_	_	_	_	_
31	interpretation	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	linear-quadratic	_	_	JJ	_	_	_	_	_
35	model	_	_	NN	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	mathematical	_	_	JJ	_	_	_	_	_
39	basis	_	_	NN	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	cellular	_	_	JJ	_	_	_	_	_
43	radiation	_	_	NN	_	_	_	_	_
44	response	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	context	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	RIANS	_	_	NNP	_	_	_	_	_
7	model	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	following	_	_	VBG	_	_	_	_	_
11	mechanistic	_	_	JJ	_	_	_	_	_
12	hypothesis	_	_	NN	_	_	_	_	_
13	has	_	_	VBZ	_	_	_	_	_
14	been	_	_	VBN	_	_	_	_	_
15	proposed	_	_	VBN	_	_	_	_	_
16	:	_	_	:	_	_	_	_	_
17	after	_	_	IN	_	_	_	_	_
18	irradiation	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	cytoplasmic	_	_	JJ	_	_	_	_	_
21	trans-auto-phosphorylated	_	_	JJ	_	_	_	_	_
22	dimeric	_	_	JJ	_	_	_	_	_
23	forms	_	_	NNS	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	ATM	_	_	NN	_	_	_	_	_
26	become	_	_	VBP	_	_	_	_	_
27	monomeric	_	_	JJ	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	diffuse	_	_	JJ	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	nucleus	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	nucleus	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	active	_	_	JJ	_	_	_	_	_
6	ATM	_	_	NN	_	_	_	_	_
7	monomers	_	_	NNS	_	_	_	_	_
8	phosphorylate	_	_	NN	_	_	_	_	_
9	H2AX	_	_	NN	_	_	_	_	_
10	molecules	_	_	NNS	_	_	_	_	_
11	at	_	_	IN	_	_	_	_	_
12	DSB	_	_	NNP	_	_	_	_	_
13	sites	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	which	_	_	WDT	_	_	_	_	_
16	activates	_	_	VBZ	_	_	_	_	_
17	NHEJ	_	_	NNP	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	ATM	_	_	NN	_	_	_	_	_
3	monomers	_	_	NNS	_	_	_	_	_
4	will	_	_	MD	_	_	_	_	_
5	re-dimerize	_	_	VB	_	_	_	_	_
6	during	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	DSB	_	_	NN	_	_	_	_	_
9	repair	_	_	NN	_	_	_	_	_
10	process	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Once	_	_	RB	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	nucleus	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	ATM	_	_	NNP	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	inhibit	_	_	VB	_	_	_	_	_
9	MRE11	_	_	NNP	_	_	_	_	_
10	nuclease	_	_	NN	_	_	_	_	_
11	activity	_	_	NN	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	any	_	_	DT	_	_	_	_	_
14	other	_	_	JJ	_	_	_	_	_
15	actor	_	_	NN	_	_	_	_	_
16	responsible	_	_	JJ	_	_	_	_	_
17	for	_	_	IN	_	_	_	_	_
18	genomic	_	_	JJ	_	_	_	_	_
19	instability	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	By	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	moderate	_	_	JJ	_	_	_	_	_
8	radiosensitivity	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	over-expressed	_	_	VBN	_	_	_	_	_
11	ATM	_	_	NN	_	_	_	_	_
12	substrates	_	_	NNS	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	delay	_	_	VB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	RIANS	_	_	NNP	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	thereby	_	_	RB	_	_	_	_	_
19	favoring	_	_	VBG	_	_	_	_	_
20	cancer	_	_	NN	_	_	_	_	_
21	proneness	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	aging	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	notably	_	_	RB	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	case	_	_	NN	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	huntingtin	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	neurofibromin	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	tuberin	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	6	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Three	_	_	CD	_	_	_	_	_
2	groups	_	_	NNS	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	radiosensitivity	_	_	NN	_	_	_	_	_
5	have	_	_	VBP	_	_	_	_	_
6	been	_	_	VBN	_	_	_	_	_
7	defined	_	_	VBN	_	_	_	_	_
8	:	_	_	:	_	_	_	_	_


1	Group	_	_	NN	_	_	_	_	_
2	I	_	_	PRP	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	about	_	_	RB	_	_	_	_	_
5	75	_	_	CD	_	_	_	_	_
6	%	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	85	_	_	CD	_	_	_	_	_
9	%	_	_	NN	_	_	_	_	_
10	whole	_	_	JJ	_	_	_	_	_
11	population	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	represents	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	normosensitive	_	_	JJ	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	radioresistant	_	_	JJ	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	patients	_	_	NNS	_	_	_	_	_
20	with	_	_	IN	_	_	_	_	_
21	a	_	_	DT	_	_	_	_	_
22	rapid	_	_	JJ	_	_	_	_	_
23	RIANS	_	_	NN	_	_	_	_	_
24	after	_	_	IN	_	_	_	_	_
25	2	_	_	CD	_	_	_	_	_
26	Gy	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	a	_	_	DT	_	_	_	_	_
29	low	_	_	JJ	_	_	_	_	_
30	risk	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	post-radiotherapy	_	_	JJ	_	_	_	_	_
33	tissue	_	_	NN	_	_	_	_	_
34	reaction	_	_	NN	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	cancer	_	_	NN	_	_	_	_	_


1	Group	_	_	NN	_	_	_	_	_
2	II	_	_	NNP	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	about	_	_	RB	_	_	_	_	_
5	5	_	_	CD	_	_	_	_	_
6	–	_	_	TO	_	_	_	_	_
7	20	_	_	CD	_	_	_	_	_
8	%	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	whole	_	_	JJ	_	_	_	_	_
11	population	_	_	NN	_	_	_	_	_
12	)	_	_	-RRB-	_	_	_	_	_
13	represents	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	patients	_	_	NNS	_	_	_	_	_
16	who	_	_	WP	_	_	_	_	_
17	elicit	_	_	VBP	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	moderate	_	_	JJ	_	_	_	_	_
20	radiosensitivity	_	_	NN	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	delay	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	RIANS	_	_	NNP	_	_	_	_	_
27	due	_	_	JJ	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	sequestration	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	ATM	_	_	NN	_	_	_	_	_
33	by	_	_	IN	_	_	_	_	_
34	mutated	_	_	VBN	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	over-expressed	_	_	JJ	_	_	_	_	_
37	substrates	_	_	NNS	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	patients	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	moderately	_	_	RB	_	_	_	_	_
5	radiosensitive	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	have	_	_	VB	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	high	_	_	JJ	_	_	_	_	_
11	risk	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	cancer	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	neurodegeneration	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Group	_	_	NNP	_	_	_	_	_
2	III	_	_	NNP	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	<1	_	_	CD	_	_	_	_	_
5	%	_	_	NN	_	_	_	_	_
6	whole	_	_	JJ	_	_	_	_	_
7	population	_	_	NN	_	_	_	_	_
8	)	_	_	-RRB-	_	_	_	_	_
9	represents	_	_	VBZ	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	ATM	_	_	NNP	_	_	_	_	_
12	-mutated	_	_	VBN	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	no	_	_	DT	_	_	_	_	_
16	functional	_	_	JJ	_	_	_	_	_
17	ATM	_	_	NN	_	_	_	_	_
18	kinase	_	_	NN	_	_	_	_	_
19	or	_	_	CC	_	_	_	_	_
20	those	_	_	DT	_	_	_	_	_
21	who	_	_	WP	_	_	_	_	_
22	show	_	_	VBP	_	_	_	_	_
23	strong	_	_	JJ	_	_	_	_	_
24	DSB	_	_	NN	_	_	_	_	_
25	repair	_	_	NN	_	_	_	_	_
26	defects	_	_	NNS	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	like	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	LIG4	_	_	NNP	_	_	_	_	_
31	-mutated	_	_	VBN	_	_	_	_	_
32	patient	_	_	NN	_	_	_	_	_
33	described	_	_	VBN	_	_	_	_	_
34	above	_	_	RB	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	,	_	_	,	_	_	_	_	_
37	hyper-radiosensitivity	_	_	NN	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	either	_	_	CC	_	_	_	_	_
41	high	_	_	JJ	_	_	_	_	_
42	cancer	_	_	NN	_	_	_	_	_
43	proneness	_	_	NN	_	_	_	_	_
44	or	_	_	CC	_	_	_	_	_
45	severe	_	_	JJ	_	_	_	_	_
46	accelerated	_	_	VBN	_	_	_	_	_
47	aging	_	_	NN	_	_	_	_	_
48	.	_	_	.	_	_	_	_	_


1	While	_	_	IN	_	_	_	_	_
2	it	_	_	PRP	_	_	_	_	_
3	provides	_	_	VBZ	_	_	_	_	_
4	relevant	_	_	JJ	_	_	_	_	_
5	explanation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	radiosensitivity	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	syndromes	_	_	NNS	_	_	_	_	_
11	caused	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	mutations	_	_	NNS	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	cytoplasmic	_	_	JJ	_	_	_	_	_
16	proteins	_	_	NNS	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	RIANS	_	_	NNP	_	_	_	_	_
20	model	_	_	NN	_	_	_	_	_
21	appears	_	_	VBZ	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	compatible	_	_	JJ	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	all	_	_	PDT	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	alternative	_	_	JJ	_	_	_	_	_
29	models	_	_	NNS	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	as	_	_	IN	_	_	_	_	_
32	ATM	_	_	NNP	_	_	_	_	_
33	is	_	_	VBZ	_	_	_	_	_
34	upstream	_	_	JJ	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	all	_	_	PDT	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	cascades	_	_	NNS	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	radiation-induced	_	_	JJ	_	_	_	_	_
41	phosphorylations	_	_	NNS	_	_	_	_	_
42	involved	_	_	VBN	_	_	_	_	_
43	in	_	_	IN	_	_	_	_	_
44	the	_	_	DT	_	_	_	_	_
45	individual	_	_	JJ	_	_	_	_	_
46	response	_	_	NN	_	_	_	_	_
47	to	_	_	TO	_	_	_	_	_
48	IR	_	_	NNP	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	Obviously	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	further	_	_	JJR	_	_	_	_	_
4	investigations	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	needed	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	better	_	_	RBR	_	_	_	_	_
9	understand	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	direct	_	_	JJ	_	_	_	_	_
12	or	_	_	CC	_	_	_	_	_
13	indirect	_	_	JJ	_	_	_	_	_
14	role	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	cytoplasmic	_	_	JJ	_	_	_	_	_
17	ATM	_	_	NN	_	_	_	_	_
18	forms	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	activation	_	_	NN	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	inhibition	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	DSB	_	_	NN	_	_	_	_	_
27	repair	_	_	NN	_	_	_	_	_
28	pathways	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

